Journal · Updated 2026-08-11
Saxenda vs Wegovy: What the Older Daily Drug Still Answers in 2026
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
The comparison is generational: Saxenda (liraglutide 3.0) is a daily injection averaging about 8% loss in its SCALE trial program; Wegovy (semaglutide 2.4) is weekly at 14.9% — nearly double the result at a seventh the injection frequency, which is why the market moved and why no efficacy-first buyer starts at liraglutide in 2026. What keeps the older molecule on the board: generic liraglutide began arriving in 2024, creating the class's first true generic pricing lane (variable, sometimes undercutting brand semaglutide channels — worth a quote if cash-pay and coverage-blocked); some formularies still step-therapy through it; its longer daily half-life profile suits a few clinical edge cases; and its pediatric-label history predates the newer agents'. The honest routing: Wegovy-class first by default; liraglutide as the answer to three specific questions — a formulary that mandates it, a generic quote that genuinely wins your math, or a clinician's case-specific reason.
What the older drug's data still teaches
SCALE's ~8% at 56 weeks established the playbook everything since followed — titrated dosing, GI-dominant side effects, regain on discontinuation — and its decade of post-market experience is the class's deepest safety archive, a genuine reassurance that transfers by mechanism to its successors. The daily-versus-weekly trade runs one direction for adherence (weekly wins decisively in persistence data) with one counterpoint: a daily drug clears faster, which occasionally matters around procedures and side-effect management. The generic lane deserves sober framing: pricing varies widely by pharmacy and quantity, "generic" applies to the diabetes-dose products more cleanly than the 3.0 weight dose in some channels, and a quoted price only competes if it beats the semaglutide board's $99–$149 floor tier — a bar it sometimes clears and often doesn't. Verdict shape: Saxenda-class liraglutide is 2026's contingency answer — the drug you take because a formulary, a price quote, or a clinical particular said so — and a perfectly respectable one, backed by the archive that built the category the newer drugs now lead.
Questions people ask
Is Saxenda as good as Wegovy?
On averages, no: SCALE's ~8% at 56 weeks versus STEP's 14.9% at 68, daily injections versus weekly. Liraglutide's 2026 role is situational — formulary step-therapy, generic pricing that occasionally wins, specific clinical reasoning — not head-to-head preference.
Is there a generic version of these weight-loss drugs?
Liraglutide is the class's first: generics began arriving in 2024, with pricing that varies widely by pharmacy and channel. No semaglutide or tirzepatide generic exists. A generic liraglutide quote is worth getting when cash-pay — then compare it against the $99–$149 semaglutide floor tier before deciding.
Why would anyone still be prescribed Saxenda in 2026?
Three live reasons: a formulary that step-therapies through it before covering newer agents, a generic price that beats your alternatives, or clinician judgment (its daily dosing clears faster; its post-market archive is the class's longest). Otherwise the weekly drugs lead on results and adherence.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.